GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Additional Paid-In Capital

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Additional Paid-In Capital : NT$591.12 Mil(As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals Additional Paid-In Capital?


Great Novel Therapeutics Biotech & Medicals's quarterly additional paid-in capital increased from Dec. 2022 (NT$363.05 Mil) to Jun. 2023 (NT$587.88 Mil) and increased from Jun. 2023 (NT$587.88 Mil) to Dec. 2023 (NT$591.12 Mil).

Great Novel Therapeutics Biotech & Medicals's annual additional paid-in capital increased from Dec. 2021 (NT$221.94 Mil) to Dec. 2022 (NT$363.05 Mil) and increased from Dec. 2022 (NT$363.05 Mil) to Dec. 2023 (NT$591.12 Mil).


Great Novel Therapeutics Biotech & Medicals Additional Paid-In Capital Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals Additional Paid-In Capital Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 96.57 138.28 221.94 363.05 591.12

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only 221.94 224.40 363.05 587.88 591.12

Great Novel Therapeutics Biotech & Medicals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Great Novel Therapeutics Biotech & Medicals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Traded in Other Exchanges
N/A
Address
No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines